Cancer vaccines inducing antibody production: more pros than cons
Authors:
- Erika Jensen-JarolimEJErika Jensen-Jarolim
- Josef SingerJSJosef Singer
- 1 September 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 10 (9) , 1281-1289
Abstract
To date, passive immunotherapy with monoclonal antibodies is a well-established option in clinical oncology. By contrast, anticancer vaccines are less advanced, with the exception of successfully applied prophylactic vaccines against oncogenic virus infections. The creation of therapeutic vaccines is still a great challenge mostly due to the self-nature of tumor antigens. Therapeutic vaccines may be based on patient-specific material including pulsed effector cells, or tumor-associated antigens and derivatives thereof, such as peptides, mimotopes and nucleic acids. The latter represents a more universal approach, which would set an ideal economic framework resulting in broad patient access. In this article we focus on cancer vaccines for antibody production, in particular mimotope vaccines. The collected evidence suggests that they will open up new treatment options in minimal residual disease and early stage disease.Keywords
This publication has 98 references indexed in Scilit:
- Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodiesInternational Immunology, 2011
- Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive MiceImmunity, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- The ABC of clinical and experimental adjuvants—A brief overviewImmunology Letters, 2010
- Cancer vaccine with mimotopes of tumor-associated carbohydrate antigensImmunologic Research, 2009
- Immunotherapy of autoimmunity and cancer: the penalty for successNature Reviews Immunology, 2008
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsCancer Immunology, Immunotherapy, 2008
- Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cellsClinical and Experimental Immunology, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancerClinical and Experimental Immunology, 2006